REFERENCES
1. Ulumbekova G.E., Ginoyan A.B., Khudova I.Yu. Scientific substantiation of the conditions for increasing the birth rate in the Russian Federation in the period from 2022 to 2030. ORGZDRAV: novosti, mneniya, obuchenie. Vestnik VShOUZ [ORGZDRAV: News, Opinions, Training. Bulletin of VShOUZ]. 2022; 8 (1): 4–22. DOI: https://doi.org/10.33029/2411-8621-2022-8-1-4-22 (in Russian)
2. Smelov P.A., et al. Women and men of Russia. 2020: Statistical collection. In: Rosstat. Moscow, 2020: 239 p. (in Russian)
3. Federal State Statistics Service. Brief report on the results of the sample survey «Reproductive health survey Russia 2011». URL: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/healthcare (in Russian)
4. Rosstat data, 2017. URL: http://www.gks.ru/free_doc/doc_2017/zdrav17.pdf (in Russian)
5. Zhang L., Zetter M.A., Guerra E.C., Hernández V.S., Mahata S.K., Eiden L.E. ACE2 in the second act of COVID-19 syndrome: peptide dysregulation and possible correction with oestrogen. J Neuroendocrinol. 2021; 33: e12935. DOI: https://doi.org/10.1111/jne.12935
6. Makatsariya A.D., Slukhanchuk E.V., Bitsadze V.O., Khizroeva J.K., Tret’ya- kova M.V., Tsibizova V.I., et al. COVID-19, hemostasis disorders and risk of thrombotic complications. Vestnik RAMN [Bulletin of the Russian Academy of Medical Sciences]. 2020; 75 (4): 306–17. DOI: https://doi.org/10.15690/vramn1368 (in Russian)
7. Cagnacci A., Londero A.P., Xholli A. COVID-19 and hormonal contraception. Case Rep Womens Health. 2022; 34: e00389. DOI: https://doi.org/10.1016/j.crwh.2022.e00389 Epub 2022 Jan 25. PMID: 35096531; PMCID: PMC8788094.
8. Ali M., Akin A., Bahamondes L., Brache V., Habib N., Landoulsi S., et al.; WHO Study Group on Subdermal Contraceptive Implants for Women. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. Hum Reprod. 2016; 31 (11): 2491–8.
9. Foran T., Butcher B.E., Kovacs G., Bateson D., O’Connor V. Safety of insertion of the copper IUD and LNG-IUS in nulliparous women: a systematic review. Eur J Contracept Reprod Health Care. 2018; 23 (5): 379–86.
10. Limanova O.A., Torshin I.Yu., Sardaryan I.S., et al. Micronutrient provision and women’s health: intellectual analysis of clinicoepidemiological data. Voprosy ginekologii, akusherstva i perinatologii [Problems of Gynecology, Obstetrics and Perinatology]. 2014; 13 (2): 5–15. (in Russian)
11. Prilepskaya V.N., Bostandzhyan L.L. Folate contraception and clinical practice. Ginekologiya [Gynecology]. 2020; 22 (6): 101–7. (in Russian)
12. Normal pregnancy. Clinical recommendations of the Ministry of Health of the Russian Federation. Moscow, 2020. (in Russian)
13. Arya R., et al. J Neonatol. 2006; 20 (4): 316–26.
14. Taylor T.N., Farkouh R.A., Graham J.B., Colligs A., Lindemann M., Lynen R., et al. Potential reduction in neural tube defects associated with use of Metafolin-fortified oral contraceptives in the United States. Am J Obstet Gynecol. 2011; 205 (5): 460.e1–8.
15. Food & Drug Administration. URL: http://www.fda.gov/ohrms/dockets/ac/03/minutes/4002M1_Final.pdf
16. Cheschier N.; ACOG Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin. Neural tube defects. No. 44, July 2003. (Replaces committee opinion No. 252, March 2001). Int J Gynaecol Obstet. 2003; 83 (1): 123–33.
17. Am J Clin Nutr. 2003; 77 (4): 757–9.
18. De Batlle J., et al. Dietary folate intake and breast cancer risk: European prospective investigation into cancer and nutrition. J Natl Cancer Inst. 2014; 107 (1): 367.
19. Prilepskaya V.N. Contraception with folates and real clinical practice. All-Russian Scientific and Educational Forum «Mother and Child». Effektivnaya farmakoterapiya. Akusherstvo i ginekologiya. [Effective Pharmacotherapy. Obstetrics and Gynecology]. 2018; (3–4): 36–44. (in Russian)
20. Prilepskaya V.N., Dovletkhanova E.R. Hormonal contraception using a combined oral contraceptive containing estradiol valerate/dienogest. Meditsinskiy opponent [Medical Opponent]. 2022; 2 (18): 46–52. (in Russian)
21. Dinger J., Möhner S., Heinemann K. Combined oral contraceptives containing dienogest and estradiol valerate may carry a lower risk of venous and arterial thromboembolism compared to conventional preparations: results from the extended INAS-SCORE study. Front Womens Health. 2020; 5: 1–8.
22. Prilepskaya V.N., Mezhevitinova E.A., Nazarenko E.G., Gorodnova E.A. The renaissance of barrier contraception (based on the data from an international clinical trial). Ginekologiya [Gynecology]. 2021; 23 (5): 380–5. DOI: https://doi.org/10.26442/20795696.2021.5.201151 (in Russian)
23. Gollub E. Women’s barrier contraceptive methods as modern methods. Sex Health. 2011; 8 (1): 128–9.
24. Minnis A.M., Padian N.S. Effectiveness of female controlled barrier methods in preventing sexually transmitted infections and HIV: current evidence and future research directions. Sex Transm Infect. 2005; 81 (3): 193–200.
25. Tussell J. Contraceptive failure in the United States. Contraception. 2011; 83 (5): 397–404. DOI: https://doi.org/10.1016/j.contraception.2011.01.021
26. Raymond E.G., Chen P.L., Luoto J.; Spermicide Trial Group. Contraceptive effectiveness and safety of five nonoxynol-9 spermecides. A randomized trial. Obstet Gynecol. 2004; 103 (3): 430–9.
27. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP); Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018update). Baltimore and Geneva: CCP and WHO, 2018.
28. Serfaty D., Prilepskaya V., Graeslin O., et al. Contraceptive efficacy, tolerance and acceptability of a benzalkonium chloride spermicide cream in women aged over 40 years of age: interim results from a six-month, international, open-label, multicentre phase IV study. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. 2020; (4): 6–7. (in Russian)
29. Serfaty D. Contraception des femmes allaitantes: place des spermicides [Contraception in breastfeeding women: place for spermicides]. J Gynecol Obstet Biol Reprod (Paris). 2015; 44 (1): 18–27.
30. Johns Hopkins University. URL: https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6
31. Lete I. Combined hormonal contraception and COVID-1. Eur J Contracept Reprod Health Care. 2021; 26 (2): 128–31.
32. Hannaford P.C., Iversen L., Macfarlane T.V., Elliott A.M., Angus V., Lee A.J. Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners’ Oral Contraception Study. BMJ. 2010; 340: c927.